Document:

Exhibit 4.1

 

 

 

FIRST SUPPLEMENTAL INDENTURE

 

Supplementing the Indenture
dated as of February 16, 2018

 

AVADEL FINANCE CAYMAN LIMITED,
as Notes Issuer

 

and

 

AVADEL PHARMACEUTICALS PLC,
as Guarantor

 

and

 

THE BANK OF NEW YORK MELLON,
as Trustee

 

 

 

4.50% Exchangeable Senior Notes
due 2023

 

Dated as of February 6, 2019

 

 

 

     

     

    

 

FIRST SUPPLEMENTAL
INDENTURE, dated as of February 6, 2019 (this “First Supplemental Indenture”), by and among Avadel Finance Cayman
Limited, a Cayman Islands exempted company limited by its shares (the “Company”), Avadel Pharmaceuticals plc,
a public limited company incorporated under the laws of Ireland (“Avadel”), and The Bank of New York Mellon,
a New York banking corporation (the “Trustee”), as Trustee under the Indenture dated as of February 16, 2018
by and among the Company, Avadel and the Trustee (the “Indenture”). Capitalized terms used herein and not otherwise
defined herein shall have the meanings ascribed thereto in the Indenture.

 

RECITALS

 

WHEREAS, the Company
and Avadel have heretofore executed and delivered to the Trustee the Indenture providing for the issuance of $143,750,000 aggregate
principal amount of 4.50% Exchangeable Senior Notes due 2023 (the “Notes”).

 

WHEREAS, Avadel Specialty
Pharmaceuticals, LLC, a Delaware limited liability company (“Specialty Pharma”), is an indirect, wholly owned
subsidiary of Avadel.

 

WHEREAS, Specialty
Pharma intends to become the subject of a voluntary case (the “Bankruptcy Case”) under the United States federal
bankruptcy laws (the “Bankruptcy Code”) before the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy
Court” and, such case, the “Specialty Pharma Bankruptcy Proceeding”).

 

WHEREAS, in connection
with the Bankruptcy Case, Specialty Pharma intends to transfer or otherwise dispose of any or all of its assets pursuant to (x)
one or more orders entered by the Bankruptcy Court pursuant to the Bankruptcy Code or (y) a plan of reorganization or liquidation,
in either case as confirmed by the Bankruptcy Court (each, a “Specialty Pharma Asset Transfer”).

 

WHEREAS, Section
6.01(i) of the Indenture provides, among other things, that the commencement of a voluntary case or other proceeding seeking liquidation,
reorganization or other relief under any bankruptcy or similar laws with respect to the Company, Avadel or any Significant Subsidiary
is an Event of Default.

 

WHEREAS, Specialty
Pharma is a Significant Subsidiary for all purposes under the Indenture.

 

WHEREAS, Section
11.01 of the Indenture provides, among other things, that neither the Company nor Avadel shall consolidate or enter into a scheme
or arrangement with, merge with or into, or sell, convey, transfer or lease all or substantially all of their respective properties
and assets to, another Person except under certain conditions specified therein.

 

WHEREAS, the Company
and Avadel desire to amend Sections 1.01, 6.01(i) and 11.01 of the Indenture to ensure that neither the Specialty Pharma Bankruptcy
Proceeding, nor any Specialty Pharma Asset Transfer, will result in an Event of Default under the Indenture or otherwise violate
the Notes or the Indenture.

 

WHEREAS, pursuant
to Sections 10.05 and 17.06 of the Indenture, there have been delivered to the Trustee on the date hereof an Officers’ Certificate
and Opinion of Counsel certifying, among other things, that all conditions precedent under the Indenture relating to execution
and delivery of this First Supplemental Indenture have been complied with.

 

     

     

    

 

WHEREAS, the Holders
of at least a majority of the aggregate principal amount of the Notes then outstanding have consented to the amendments to the
Indenture set forth herein pursuant to Section 10.02 of the Indenture.

 

WHEREAS, all things
necessary to make this First Supplemental Indenture a valid supplement to the Indenture, according to the terms of this First Supplemental
Indenture and the terms of the Indenture, have been done.

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual premises and covenants contained herein and for other good and valuable consideration,
the parties hereto agree as follows:

 

ARTICLE 1

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION

 

Section 1.01 References.
Each reference to a particular section set forth in this First Supplemental Indenture shall, unless otherwise stated or the context
otherwise requires, refer to this First Supplemental Indenture.

 

ARTICLE
2

AMENDMENTS

 

Section 2.01 Amendment
to Section 1.01 of the Indenture. Section 1.01 of the Indenture is hereby amended by adding the following definitions (each
of which shall be included in alphabetical order within Section 1.01):

 

“Bankruptcy Court”
means the United States Bankruptcy Court for the District of Delaware.

 

“Specialty Pharma”
means Avadel Specialty Pharmaceuticals, LLC, a Delaware limited liability company and an indirect, wholly owned subsidiary of Avadel.

 

“Specialty Pharma Asset
Transfer” means any transfer or other disposition of any or all of Specialty Pharma’s assets to one or more Persons
other than any Affiliate pursuant to (x) one or more orders entered by the Bankruptcy Court pursuant to the Bankruptcy Code or
(y) a plan of reorganization or liquidation, in either case as confirmed by the Bankruptcy Court.

 

“Specialty Pharma Bankruptcy
Proceeding” means a voluntary case commenced pursuant to any chapter or provision of the Bankruptcy Code before the Bankruptcy
Court no later than February 15, 2019.

 

Section 2.02 Amendment
to Section 6.01(i) of the Indenture. Section 6.01(i) of the Indenture is hereby amended and restated in its entirety to read
as follows:

 

    	 	2	 

     

    

 

“(i) the Company, Avadel
or any Significant Subsidiary of Avadel shall commence a voluntary case or other proceeding seeking liquidation, reorganization
or other relief with respect to the Company, Avadel or any such Significant Subsidiary or its debts under any bankruptcy, insolvency,
examinership or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, examiner, liquidator,
custodian or other similar official of the Company, Avadel or any such Significant Subsidiary or any substantial part of its property,
or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or
other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally
to pay its debts as they become due; provided, that, notwithstanding the foregoing, the commencement and prosecution of
the Specialty Pharma Bankruptcy Proceeding shall not constitute an Event of Default;”

 

Section 2.03 Amendment
to Section 11.01 of the Indenture. Section 11.01 of the Indenture is hereby amended by adding the following to the last paragraph
of Section 11.01:

 

“Anything to the contrary
(including without limitation the preceding sentence) notwithstanding, and for the avoidance of doubt, any Specialty Pharma Asset
Transfer shall not be deemed to be the sale, conveyance, transfer or lease of all or substantially all of the properties and assets
of Avadel to another Person.”

 

ARTICLE 3

MISCELLANEOUS PROVISIONS

 

Section 3.01 Confirmation
of Indenture. The Indenture, as supplemented and amended by this First Supplemental Indenture, is in all respects ratified
and confirmed, and the Indenture and this First Supplemental Indenture shall be read, taken and construed as one and the same instrument.

 

Section 3.02 Governing
Law. THIS FIRST SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. THE TRUSTEE, THE COMPANY, AVADEL,
AND THE HOLDERS AGREE TO SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK IN ANY ACTION OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS FIRST SUPPLEMENTAL INDENTURE.

 

Section 3.03 Separability.
In case any provision in this First Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

Section 3.04 Counterparts.
This First Supplemental Indenture may be executed in several counterparts, each of which shall be an original and all of which
shall constitute but one and the same document.

 

Section 3.05 Effect
of Headings. The Section headings herein are for convenience of reference only, are not to be considered a part hereof and
shall in no way modify or restrict any of the terms and provisions hereof.

 

    	 	3	 

     

    

 

Section 3.06 Trustee
Makes No Representations. The Trustee makes no representations as to the validity or sufficiency of this First Supplemental
Indenture. The recitals of fact contained herein shall be taken as statements solely of the Company and Avadel, and the Trustee
assumes no responsibility for the correctness or sufficiency thereof.

 

Section 3.07 Successors
and Assigns. All agreements of the Company and Avadel in this First Supplemental Indenture shall bind their respective successors.

 

[The remainder of this page is intentionally
left blank.]

 

    	 	4	 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this First Supplemental Indenture to be duly executed as of the day and year first above written.

 

	 	AVADEL FINANCE CAYMAN LIMITED,
	 	a Cayman Island exempted company limited by its shares
	 	 
	 	By:	/s/ Michael F. Kanan
	 	 	Name:	Michael F. Kanan
	 	 	Title:	Treasurer
	 	 
	 	AVADEL PHARMACEUTICALS PLC,
	 	a public limited company incorporated under the laws of Ireland
	 	 
	 	By:	/s/ Michael F. Kanan
	 	 	Name:	Michael F. Kanan
	 	 	Title:	Senior Vice President and
	 	 	 	Chief Financial Officer

 

[Signature Page to First Supplemental Indenture (Exchangeable Senior Notes due 2023)]

 

     

     

    

 

	 	THE BANK OF NEW YORK MELLON, as
	 	Trustee
	 	 
	 	By:	/s/ Wanda Camacho
	 	 	Name:	Wanda Camacho
	 	 	Title:	Vice President

 

[Signature Page to First Supplemental Indenture (Exchangeable Senior Notes due 2023)]Exhibit

Exhibit 10.1

EXECUTION VERSION

SECOND AMENDMENT TO  
THIRD AMENDED AND RESTATED CREDIT AGREEMENT

This SECOND AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT, dated as of February 6, 2019 (this “Amendment”), is by and among THE HAIN CELESTIAL GROUP, INC., a Delaware corporation (the “Company”), HAIN PURE PROTEIN CORPORATION, a Delaware corporation and a wholly-owned Subsidiary of the Company (“HPPC” and, together with the Company, collectively, the “Borrowers”) the Lenders (as defined below) party hereto and  BANK OF AMERICA, N.A., as administrative agent (in such capacity, the “Administrative Agent”).  Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Credit Agreement (as defined below).

W I T N E S S E T H

WHEREAS, the Company, HPPC, certain other wholly-owned Subsidiaries of the Company party thereto from time to time, each lender from time to time party thereto (collectively, the “Lenders” and individually, a “Lender”) and the Administrative Agent are parties to that certain Third Amended and Restated Credit Agreement, dated as of February 6, 2018 (as amended, supplemented, extended, restated or otherwise modified from time to time, the “Credit Agreement”);

WHEREAS, the Company has requested that the Lenders amend certain provisions of the Credit Agreement; and

WHEREAS, the Lenders party hereto are willing to make such amendments to the Credit Agreement, in accordance with and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:
Article 1 
AMENDMENTS TO CREDIT AGREEMENT
1.1    Amendment to Section 1.01 (“Defined Terms”).  The definition of “Applicable Rate” appearing in Section 1.01 of the Credit Agreement is hereby amended by (a) amending and restating the table set forth in such definition to read as follows:

	
					
	Applicable Rate

	Pricing Level
	Consolidated Leverage Ratio
	Commitment Fee
	Eurocurrency Rate Loans + 
Global Swing Line Loans + 
Letters of 
Credit
	Base Rate +

	

1

2
	

≥ 3.50:1.00

≥ 3.00:1.00 but  
< 3.50:1.00 
	

0.350%

0.300%
	

1.900%

1.700%
	

0.900%

0.700%

	 
	 
	 
	 
	 

	3
	≥ 2.50:1.00 but
< 3.00:1.00
	0.275%
	1.500%
	 
0.500%

	4
	≥ 2.00:1.00 but
< 2.50:1.00
	0.250%
	1.375%
	 
0.375%

	5
	≥ 1.50:1.00 but
< 2.00:1.00
	0.225%
	1.250%
	 
0.250%

	6
	≥ 1.00:1.00 but
< 1.50:1.00
	0.200%
	1.000%
	 
0.000%

	7
	< 1.00:1.00
	0.200%
	0.875%
	0.000%

and (b) deleting in its entirety the second sentence of the paragraph appearing immediately after the table set forth in such definition.
1.2    Amendment to Section 7.11 (“Financial Covenants”).  Section 7.11(b) of the Credit Agreement is hereby amended and restated in its entirety to read as follows: 
(b)    Consolidated Leverage Ratio.  Permit the Consolidated Leverage Ratio as of the end of any fiscal quarter of the Company occurring during any period set forth below to be greater than the ratio set forth below opposite such period:

	
		
	Fiscal Quarter Ending
	Maximum Consolidated Leverage Ratio

	Closing Date through (and including) September 30, 2018
	3.50:1.00

	October 1, 2018 through (and including) December 31, 2018
	4.00:1.00

	January 1, 2019 through (and including) June 30, 2019
	3.75:1.00

	July 1, 2019 and thereafter
	3.50:1.00

2

provided that, from and after January 1, 2019, as of any fiscal quarter end when the Consolidated Leverage Ratio is otherwise required to be either 3.75:1.00 or 3.50:1.00 as set forth in the above table, the Consolidated Leverage Ratio may exceed such required ratio at any time during a Transition Period if any such excess is a direct result of the Company or any Subsidiary creating, assuming, incurring, guaranteeing or otherwise becoming liable in respect of Acquisition Debt, but only so long as the Consolidated Leverage Ratio at all times during such Transition Period shall not exceed 4.00:1.00.

Article 2

CONDITIONS TO EFFECTIVENESS

2.1    Closing Conditions.  This Amendment shall be deemed effective as of December 31, 2018 (the “Second Amendment Effective Date”) upon satisfaction of the following conditions (in each case, in form and substance reasonably acceptable to the Administrative Agent):

(a)    Executed Amendment.  The Administrative Agent shall have received a copy of this Amendment duly executed by each of the Borrowers, the Required Lenders and the Administrative Agent.
(b)    Default.  After giving effect to this Amendment, no Default or Event of Default shall exist.
(c)    Fees, Costs and Expenses.  The Administrative Agent shall have received from the Company:
(i)    For the account of each Lender that executes and delivers a signature page hereto to the Administrative Agent by 5:00 p.m. Eastern time on or before February 5, 2019 (each such Lender, a “Consenting Lender”, and collectively, the “Consenting Lenders”), an amendment fee in an amount equal to five (5) basis points on (A) the aggregate Revolving Commitments of such Consenting Lender (prior to giving effect to this Amendment) and (B) the outstanding principal amount of the Term Loans held by such Consenting Lender.
(ii)    The Administrative Agent shall have received from the Company such other fees, costs and expenses that are payable in connection with the consummation of the transactions contemplated hereby and Holland & Knight LLP shall have received from the Company payment of all outstanding fees and expenses previously incurred and all fees and expenses incurred in connection with this Amendment.
(d)    Miscellaneous.  All other documents and legal matters in connection with the transactions contemplated by this Amendment shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel.
Article 3
MISCELLANEOUS
3.1    Amended Terms.  On and after the Second Amendment Effective Date, all references to the Credit Agreement in each of the Loan Documents shall hereafter mean the Credit Agreement as amended 

3

by this Amendment.  Except as specifically amended hereby or otherwise agreed, the Credit Agreement is hereby ratified and confirmed and shall remain in full force and effect according to its terms.
3.2    FATCA.  For purposes of determining withholding Taxes imposed under the Foreign Account Tax Compliance Act (FATCA), from and after the Second Amendment Effective Date, the Borrower and the Administrative Agent shall treat (and the Lenders hereby authorize the Administrative Agent to treat) the Credit Agreement as not qualifying as a “grandfathered obligation” within the meaning of Treasury Regulation Section 1.1471-2(b)(2)(i).
3.3    Representations and Warranties of Loan Parties.  Each of the Borrowers represents and warrants as follows:
(a)    It has taken all necessary action to authorize the execution, delivery and performance of this Amendment.
(b)    This Amendment has been duly executed and delivered by such Borrower and constitutes such Borrower’s legal, valid and binding obligation, enforceable in accordance with its terms, except as such enforceability may be subject to (i) bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity).
(c)    No consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental authority or third party is required in connection with the execution, delivery or performance by such Person of this Amendment.
(d)    The representations and warranties of the Company and each other Loan Party contained in Article V of the Credit Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects on and as of the Second Amendment Effective Date, except that (i) such representations and warranties that specifically refer to an earlier date shall be true and correct in all material respects as of such earlier date, (ii) such representations and warranties shall be true and correct in all respects to the extent they are qualified by a materiality standard and (iii) the representations and warranties contained in clauses (a) and (c) of Section 5.03 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (c), respectively, of Section 6.01 of the Credit Agreement.
(e)    As of the Second Amendment Effective Date, no event has occurred and is continuing which constitutes a Default or an Event of Default.
(f)    The Obligations are not reduced or modified by this Amendment and are not subject to any offsets, defenses or counterclaims.
3.4    Reaffirmation of Obligations.  Each Borrower hereby ratifies the Credit Agreement and each other Loan Document to which it is a party, and acknowledges and reaffirms (a) that it is bound by all terms of the Credit Agreement and each such Loan Document applicable to it and (b) that it is responsible for the observance and full performance of its respective Obligations.

4

3.5    Loan Document.  This Amendment shall constitute a Loan Document under the terms of the Credit Agreement.
3.6    Expenses.  The Borrower agrees to pay all reasonable costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment, including without limitation the reasonable fees and expenses of the Administrative Agent’s legal counsel.
3.7    Further Assurances.  The Loan Parties agree to promptly take such action, upon the request of the Administrative Agent, as is necessary to carry out the intent of this Amendment.
3.8    Entirety.  This Amendment and the other Loan Documents embody the entire agreement among the parties hereto and supersede all prior agreements and understandings, oral or written, if any, relating to the subject matter hereof.
3.9    Counterparts; Telecopy.  This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment or any other document required to be delivered hereunder, by fax transmission or e-mail transmission (e.g. “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Agreement.  Without limiting the foregoing, upon the request of any party, such fax transmission or e-mail transmission shall be promptly followed by such manually executed counterpart.
3.10    No Actions, Claims, Etc.  As of the date hereof, each of the Loan Parties hereby acknowledges and confirms that it has no knowledge of any actions, causes of action, claims, demands, damages and liabilities of whatever kind or nature, in law or in equity, against the Administrative Agent, the Lenders, or the Administrative Agent’s or the Lenders’ respective officers, employees, representatives, agents, counsel or directors arising from any action by such Persons, or failure of such Persons to act under the Credit Agreement on or prior to the date hereof.  
3.11    GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK, INCLUDING FOR SUCH PURPOSES SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK.
3.12    Successors and Assigns.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.
3.13    Consent to Jurisdiction; Service of Process; Waiver of Jury Trial.  The jurisdiction, service of process and waiver of jury trial provisions set forth in Sections 10.14 and 10.15 of the Credit Agreement are hereby incorporated by reference, mutatis mutandis.

5

IN WITNESS WHEREOF the parties hereto have caused this Amendment to be duly executed on the date first above written.

BORROWERS:

THE HAIN CELESTIAL GROUP, INC.

By: /s/ James Langrock              
       Name:  James Langrock
       Title:    Executive Vice President and
      Chief Financial Officer

HAIN PURE PROTEIN CORPORATION

By: /s/ James Langrock              
       Name:  James Langrock
       Title:    Executive Vice President and
      Chief Financial Officer

    

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

ADMINISTRATIVE AGENT:

BANK OF AMERICA, N.A.,
  as Administrative Agent

By: /s/ Ronaldo Naval              
       Name:  Ronaldo Naval
       Title:    Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

 LENDERS:    

BANK OF AMERICA, N.A.,
  as a Lender

By: /s/ Jana L. Baker              
       Name:  Jana L. Baker
       Title:    Senior Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

WELLS FARGO BANK, N.A.,
  as a Lender 

By: /s/ Stephanie Allegra              
       Name:  Stephanie Allegra
       Title:    Senior Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

JPMORGAN CHASE BANK, N.A.,
  as a Lender 

By: /s/ Anthony Galea              
       Name:  Anthony Galea
       Title:    Executive Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

CITIZENS BANK, N.A.,
  as a Lender 

By: /s/ Barrett D Bencivenga              
       Name:  Barrett D Bencivenga
       Title:    Managing Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

FARM CREDIT EAST, ACA,
  as a Lender 

By: /s/ Justin Brown              
       Name:  Justin Brown
       Title:    Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

HSBC BANK USA, N.A.,
  as a Lender 

By: /s/ Emily E. Barker           
       Name:  Emily E. Barker 
       Title:    Vice President #22403

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

COBANK, ACB
  as a Lender 

By: /s/ Austin Taylor              
       Name:  Austin Taylor
       Title:    Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

CAPITAL ONE, NATIONAL ASSOCIATION
  as a Lender 
By: /s/ Michael Sullivan              
       Name:  Michael Sullivan
       Title:    Senior Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

KEYBANK NATIONAL ASSOCIATION,
  as a Lender 

By: /s/ Thomas A. Crandell              
       Name:  Thomas A. Crandell
       Title:    Senior Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

COÖPERATIEVE RABOBANK U.A., NEW YORK BRANCH,
  as a Lender 

By: /s/ Chris Grimes              
       Name:  Chris Grimes
       Title:    Executive Director

By: /s/ Claire Laury              
       Name:  Claire Laury
       Title:    Executive Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

SUNTRUST BANK,
  as a Lender 

By: /s/ Tesha Winslow              
       Name:  Tesha Winslow
       Title:    Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

TD BANK, N.A.,
  as a Lender 

By: /s/ Alan Garson              
       Name:  Alan Garson
       Title:    Senior Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

AGFIRST FARM CREDIT BANK,
  as a Lender 

By: /s/ Matthew Jeffords              
       Name:  Matthew Jeffords
       Title:    Vice President

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

KBC BANK N.V., NEW YORK BRANCH
  as a Lender 

By: /s/ Deborah Carlson              
       Name:  Deborah Carlson
       Title:    Director

By: /s/ Susan Silver          
       Name:  Susan Silver
       Title:    Managing Director

The Hain Celestial Group, Inc. 
Second Amendment to Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]